Cargando…

Venetoclax: A Novel Treatment for Patients With del(17p) Chronic Lymphocytic Leukemia

Detalles Bibliográficos
Autores principales:	Borg, Michelle A., Clemmons, Amber
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167086/ https://www.ncbi.nlm.nih.gov/pubmed/30310726

Ejemplares similares

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
por: Evans, Sarah S., et al.
Publicado: (2015)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
por: Schieber, Michael, et al.
Publicado: (2019)

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
por: Waggoner, Matthew, et al.
Publicado: (2022)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

P641: REAL-WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA
por: Teschemaker, Anna, et al.
Publicado: (2023)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
por: Huber, Henriette, et al.
Publicado: (2017)

Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects
por: Tariq, Saba, et al.
Publicado: (2020)

Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia
por: Molica, Stefano
Publicado: (2020)

Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia
por: Jackson, Ross A., et al.
Publicado: (2022)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
por: Muhowski, Elizabeth M., et al.
Publicado: (2022)

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies
por: Sharman, Jeffrey P., et al.
Publicado: (2022)

Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?
por: Abdel-Samad, Nizar, et al.
Publicado: (2021)

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
por: Samuels, Courtney, et al.
Publicado: (2021)

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
por: Herling, Carmen D., et al.
Publicado: (2018)

Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease
por: Sugiura, Hiroyuki, et al.
Publicado: (2022)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Tumor Lysis Syndrome Caused by Unrecognized Richter’s Transformation of Chronic Lymphocytic Leukemia: Treatment With Venetoclax for Suspected Disease Progression
por: Chango Azanza, Juan Jose, et al.
Publicado: (2020)

Treatment with Venetoclax for Chronic Lymphocytic Leukemia with the Highest Known White Blood Cell Count: Safe and Effective
por: Sönmez, Mehmet, et al.
Publicado: (2021)

Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells
por: Avsec, Damjan, et al.
Publicado: (2021)

The Difficult-to-Treat del 17 p Patient—A Case Report in Chronic Lymphocytic Leukemia
por: Moldovianu, Ana-Maria, et al.
Publicado: (2021)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
por: Ferrarini, Isacco, et al.
Publicado: (2022)

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
por: Izutsu, Koji, et al.
Publicado: (2023)

Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood‐brain barrier be a disease “sanctuary” during venetoclax treatment?
por: Dimou, Maria, et al.
Publicado: (2021)

Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
por: Hampel, Paul J., et al.
Publicado: (2021)

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
por: Avsec, Damjan, et al.
Publicado: (2022)

P1713: VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
por: Kanevsky, D., et al.
Publicado: (2022)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
por: Siddiqui, Maria Tariq, et al.
Publicado: (2021)

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
por: Tam, Constantine S., et al.
Publicado: (2020)

Chronic lymphocytic leukemia with deletion 17p: An Indian scenario
por: Gogia, Ajay, et al.
Publicado: (2019)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2022)

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
por: Mato, Anthony R., et al.
Publicado: (2018)

Long-term effect of venetoclax therapy in a patient with the transformation of chronic lymphocytic leukemia into Richter’s syndrome
por: Tutaeva, Victoria Vladimirovna, et al.
Publicado: (2022)

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
por: Popovic, Relja, et al.
Publicado: (2021)

P634: EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Hengeveld, Paul, et al.
Publicado: (2023)

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia
por: Aumann, Shlomzion, et al.
Publicado: (2022)

Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report
por: Wang, Lei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cgc6tuen04d055860c7scer56v